Milledge brings proven experience, dynamic insights and strategic focus to neurovascular interventions developer.
PALO ALTO, Calif., April 30 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today that its directors elected Eric P. Milledge as Chairman of the Board. “Mr. Milledge brings exceptional industry experience, business acumen and leadership to Nfocus, as we advance our pursuit of break-through technologies in the dynamic field of endovascular neurosurgery,” noted President and CEO Martin S. Dieck.
“The relevance of Milledge’s 34 years of experience with Johnson & Johnson is what attracted us to him. Most recently serving as Company Group Chairman for the LifeScan division of Johnson & Johnson and as a member of the J&J Medical Devices & Diagnostics Group Operating Committee, Milledge will prove invaluable in strategically guiding us through our development, regulatory approval and commercialization process.”
“Neurovascular disease is one of the leading causes of death and disability and is still widely underserved. I am impressed with the potential of the technological advances Nfocus brings to this medical field,” said Milledge. “It is an honor and a privilege to work with the Nfocus team in bringing surgeons simpler, less invasive devices that could change the lives of millions through improved endovascular surgery outcomes.”
Milledge began with J&J in 1973. He later held positions of Company Group Chairman of Johnson & Johnson Health Care Systems, Inc., President of Ortho-McNeil, and President of Ortho Pharmaceutical Corporation.
“Nfocus has its hand on the pulse of the dynamic developments in the emerging endovascular neurosurgery field,” added Milledge. “It’s an exciting time to add strategic guidance, which can further the advancement of our product technologies.”
About Nfocus Neuromedical, Inc.
Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices). Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.
Nfocus was incubated at In-Cube Labs and is backed by Oxford Bioscience Partners, Technology Partners and DFJ-ePlanet Ventures.
To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the new Nfocus website at: www.nfocusneuro.com.
For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org
CONTACT: Martin S. Dieck, President and CEO, +1-650-845-3040,
martin@nfocusneuro.com, or Thomas W. Ross, Vice-President, +1-650-845-3042,
tom@nfocusneuro.com, both of Nfocus Neuromedical Inc.
Web site: http://www.nfocusneuro.com/
